Qiming Venture Partners is a leading venture capital firm that invests in innovative companies across China and the US. The firm focuses on early to expansion stage investments in the TMT (Technology, Media, and Telecommunications) and Healthcare sectors. Qiming has a track record of backing disruptive and high-growth companies that aim to address large, unmet market needs.

-- --

Duane Kuang

Gary Rieschel

Qiming Venture Partners

BAI Capital is focused on empowering future business leaders with expertise in China and a global network.

BAI Capital

达晨财智创业投资管理有限公司 is a venture capital firm focusing on investment in fields such as information technology, intelligent manufacturing, energy conservation, healthcare, consumer goods, enterprise services, and cultural media.

达晨财智创业投资管理有限公司

Medical Devices Venture is a holding company that develops a portfolio of investments in Med Tech start-ups. The aim is to combine the expertise of researchers in hospital and university settings with industrialization and commercialization capabilities.

Medical Devices Venture

Founded in 2006, Qiming Venture Partners is a leading venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), UBTech (SEHK:9880), Yuanxin Technology, Caidya, Belief BioMed, WeRide, Biren Technology, among many others.

Metric
Company Name	Qiming Venture Partners	BAI Capital	达晨财智创业投资管理有限公司	Medical Devices Venture
Symbol
MSH ID	COM:QIMINGVC	COM:BAI-CAP	COM:FORTUNEVC	COM:MEDICALDEVICESVENTURE
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance	Healthcare & Health Services
Industry	Venture Capital & Private Equity	Venture Capital	Venture Capital	Medical Devices
Country	HK	CN	CN	FR
Stage
Employee Count	109
Website	qimingvc.com	bai-cap.com	fortunevc.com	medicaldevicesventure.com
LinkedIn	qiming-venture-partners	bertelsmann-asia-investments	fortune-ventures	medical-devices-venture
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		447
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:QIMINGVC

Qiming Venture Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue